SMFR

Sema4 Holdings Corp. [SMFR] Stock Forecast

Q: What is Sema4 Holdings Corp. stock symbol ?

Sema4 Holdings Corp. is a US stock, located in Stamford of Ct and trading under the symbol SMFR

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SMFR Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

SMFR has more than 2 years of cash runway (32 months)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 57.77%

Earnings are expected to fall -100% next year

Profit margins (-2.6%) are lower than the previous year (-0.87%)

In the News

03:01 16 Apr 2024 SMFR

Sema4.ai Secures $30.5 Million to Bring AI to Enterprise Work

Artificial intelligence (AI) company Sema4.ai has secured $30.5 million in funding to bring open source-powered AI to enterprise work. The company aims to redefine the future of knowledge work by developing intelligent agents that transform how knowledge workers collaborate with AI, Sema4.ai said in a Monday (Jan. 29) press release.

10:29 16 Apr 2024 SMFR

Sema4: Restructuring Plan Figures Don't Add Up

Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth.

10:46 16 Apr 2024 SMFR

Sema4 Holdings Corporation (SMFR) Q3 2022 Earnings Call Transcript

Sema4 Holdings Corporation (NASDAQ:SMFR ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations & CFO Conference Call Participants Mark Massaro - BTIG David Delahunt - Goldman Sachs Operator Welcome to the Sema4 Third Quarter 2022 Earnings Conference Call. My name is Cheryl, and I will be your operator for today's call.

11:32 16 Apr 2024 SMFR

Why Sema4 Holdings Stock Is Crashing Today

The healthcare company delivered plenty of bad news in its Q2 update.

09:29 16 Apr 2024 SMFR

Sema4 Holdings Corp (SMFR) CEO Katherine Stueland on Q2 2022 Results - Earnings Call Transcript

Sema4 Holdings Corp (NASDAQ:SMFR ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations and Head of GeneDx Conference Call Participants David Delahunt - Goldman Sachs Group Matt Kim - Jeffrey Max Masucci - Cowen and Company Mark Massaro - BTIG Operator Good day, and thank you for standing by. Welcome to the Sema4 Second Quarter 2022 Earnings Conference Call.

12:02 16 Apr 2024 SMFR

Sema4 Holdings, Big Data For Precision Medicine Solutions

Big data and machine learning are booming also in healthcare, where it enables precision medicine and population health platform services. Sema4 Holdings has amassed huge amounts of medical data and a sophisticated platform in order to extract valuable insight from these for health systems, pharma companies and individuals.

01:27 16 Apr 2024 SMFR

Sema4 Holdings Corp. (SMFR) Moves to Buy: Rationale Behind the Upgrade

Sema4 Holdings Corp. (SMFR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10:52 16 Apr 2024 SMFR

Sema4 Holdings Corp. (SMFR) CEO Katherine Stueland on Q1 2022 Results - Earnings Call Transcript

Sema4 Holdings Corp. (NASDAQ:SMFR ) Q1 2022 Earnings Conference Call May 13, 2022 4:30 PM ET Company Representatives Katherine Stueland - Chief Executive Officer Eric Schadt - Founder, President and Chief R&D Officer Isaac Ro - Chief Financial Officer Joel Kaufman - Vice President of Finance and Corporate Development Conference Call Participants Mark Massaro - BTIG Max Masucci - Cowen and Company Dave Delahunt - Goldman Sachs Operator Good day! And thank you for standing by.

07:57 16 Apr 2024 SMFR

Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript

09:39 16 Apr 2024 SMFR

Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition

Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623 million. Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years.

SMFR Financial details

Company Rating

Neutral

Market Cap

246.37M

Income

-175.77M

Revenue

202.57M

Book val./share

8.78

Cash/share

5.01

Dividend

Dividend %

Employees

1.2K

Optionable

Shortable

Yes

Earnings

13 Mar 2023

P/E

-10.69

Forward P/E

PEG

1.24

P/S

1.1

P/B

18.97

P/C

P/FCF

-0.83

Quick Ratio

1.97

Current Ratio

2.29

Debt / Equity

0.25

LT Debt / Equity

0.23

EPS (TTM)

-7.51

EPS next Y

EPS next Q

EPS this Y

-86.52%

EPS next Y

EPS next 5Y

EPS last 5Y

11.16%

Revenue last 5Y

0.64%

Revenue Q/Q

7.72%

EPS Q/Q

-39.63%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-107%

ROE

-131%

ROC

-1.38%

Gross Margin

-55%

Oper. Margin

-262%

Profit Margin

-260%

Payout

Shs Outstand

793.21M

Shs Float

241.9M

Target Price

2.33

52W Range

0.22-4.09

52W High

52W Low

RSI

Rel Volume

2.34

Avg Volume

2.01M

Volume

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

Volatility

0%, 0%

Prev Close

Price

Change

SMFR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	26.95	1.15M	64.79	22.93	8.33
Net income per share	-4.26	-1.58M	-74.93	-53.63	-7.23
Operating cash flow per share	-2.57	-598.95K	-58.15	-31.18	-7.41
Free cash flow per share	-4.7	-804.59K	-64.49	-32.58	-7.64
Cash per share	0	695.45K	122.31	12.11	5.35
Book value per share	0	-2.12M	118.5	24.78	9.38
Tangible book value per share	0	-2.12M	118.5	6.55	2.28
Share holders equity per share	0	-2.12M	118.5	24.78	9.38
Interest debt per share	0	305.49K	10.89	7.38	2.34
Market cap	2.35B	56.65K	482.03M	89.16M	66.86M
Enterprise value	0	-63.05M	114.3M	37.61M	86.95M
P/E ratio	-75.95	0	-1.96	-0.16	-0.38
Price to sales ratio	12	0	2.27	0.38	0.33
POCF ratio	-125.69	0	-2.53	-0.28	-0.37
PFCF ratio	-68.86	0	-2.28	-0.27	-0.36
P/B Ratio	0	0	1.24	0.35	0.29
PTB ratio	0	0	1.24	0.35	0.29
EV to sales	0	-0.35	0.54	0.16	0.43
Enterprise value over EBITDA	0	0.28	-0.27	-0.1	-0.68
EV to operating cash flow	0	0.68	-0.6	-0.12	-0.48
EV to free cash flow	0	0.5	-0.54	-0.11	-0.47
Earnings yield	-0.01	-4.35K	-0.51	-6.16	-2.63
Free cash flow yield	-0.01	-2.21K	-0.44	-3.74	-2.78
Debt to equity	0	-0.14	0.08	0.29	0.25
Debt to assets	0	0.18	0.06	0.15	0.12
Net debt to EBITDA	0	0.28	0.87	0.13	-0.16
Current ratio	0	2.37	4.77	1.47	3.1
Interest coverage	-38.84	-97.81	-157.37	-208.19	0
Income quality	0.63	0.39	0.78	0.58	1.02
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.15	0.56	0.97	0.87	0.66
Research and developement to revenue	0.18	0.41	0.5	0.37	0.25
Intangibles to total assets	0	0	0	0.38	0.36
Capex to operating cash flow	0.83	0.34	0.11	0.04	0.03
Capex to revenue	-0.08	-0.18	-0.1	-0.06	-0.03
Capex to depreciation	-2.41	-2.72	-0.95	-0.24	-0.16
Stock based compensation to revenue	0.03	0.67	1.03	0.18	0
Graham number	0	8.7M	446.96	172.93	39.06
ROIC	0	0.95	-1.01	-1.56	-0.47
Return on tangible assets	0	-0.98	-0.44	-1.8	-0.58
Graham Net	0	-2.81M	82.82	-7.23	-3.56
Working capital	0	100.67M	382.26M	68.33M	123.52M
Tangible asset value	0	-330.05M	388.1M	67.06M	55.39M
Net current asset value	0	-407.59M	317.55M	-24.62M	-63.32M
Invested capital	0	-0.14	0.08	0.29	0.25
Average receivables	0	0	29.45M	34.95M	38.08M
Average payables	0	0	35.72M	45.36M	28.13M
Average inventory	0	0	29.21M	23.56M	11.22M
Days sales outstanding	0	65.81	45.69	67.41	59.13
Days payables outstanding	0	55.67	71.3	64.24	26.33
Days of inventory on hand	0	51.98	53.37	19.08	22.57
Receivables turnover	0	5.55	7.99	5.41	6.17
Payables turnover	0	6.56	5.12	5.68	13.86
Inventory turnover	0	7.02	6.84	19.13	16.17
ROE	0	0.75	-0.63	-2.16	-0.77
Capex per share	-2.12	-205.64K	-6.35	-1.4	-0.23

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	5.21	2.15	1.92	2.07	2.21
Net income per share	-26.23	-3.04	-1.84	-1.64	-0.99
Operating cash flow per share	-5.49	-2.77	-2.1	-1.59	-1.15
Free cash flow per share	-5.73	-2.79	-2.21	-1.59	-1.24
Cash per share	10.53	10.06	6.16	4.43	5.01
Book value per share	21.55	16.37	11.65	9.86	8.78
Tangible book value per share	5.7	7.24	4.58	3.03	2.13
Share holders equity per share	21.55	16.37	11.65	9.86	8.78
Interest debt per share	6.22	3.79	2.99	2.85	2.23
Market cap	102.54M	241.75M	151.49M	93.87M	71.44M
Enterprise value	50.99M	115.18M	70.18M	80.1M	91.53M
P/E ratio	-0.08	-0.99	-0.81	-0.55	-0.69
Price to sales ratio	1.67	5.6	3.11	1.76	1.24
POCF ratio	-1.59	-4.35	-2.83	-2.29	-2.39
PFCF ratio	-1.52	-4.32	-2.69	-2.28	-2.22
P/B Ratio	0.4	0.74	0.51	0.37	0.31
PTB ratio	0.4	0.74	0.51	0.37	0.31
EV to sales	0.83	2.67	1.44	1.5	1.59
Enterprise value over EBITDA	-0.64	-2.5	-1.78	-4.37	-5.4
EV to operating cash flow	-0.79	-2.07	-1.31	-1.95	-3.07
EV to free cash flow	-0.76	-2.06	-1.25	-1.95	-2.84
Earnings yield	-3.01	-0.25	-0.31	-0.45	-0.36
Free cash flow yield	-0.66	-0.23	-0.37	-0.44	-0.45
Debt to equity	0.29	0.23	0.25	0.29	0.25
Debt to assets	0.15	0.14	0.16	0.18	0.12
Net debt to EBITDA	0.65	2.74	2.06	0.75	-1.18
Current ratio	1.47	2.29	2.53	2.51	3.1
Interest coverage	-404.59	-75.94	-82.46	0	-24.19
Income quality	0.21	0.91	1.15	0.97	1.16
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.66	1.01	0.76	0.49	0.46
Research and developement to revenue	0.4	0.34	0.35	0.27	0.17
Intangibles to total assets	0.38	0.34	0.38	0.42	0.36
Capex to operating cash flow	0.04	0.01	0.05	0	0.08
Capex to revenue	-0.05	-0.01	-0.06	0	-0.04
Capex to depreciation	-0.08	-0.05	-0.27	-0.01	-0.35
Stock based compensation to revenue	0.01	0	0	0.01	-0.02
Graham number	112.77	33.46	21.95	19.07	14
ROIC	-0.83	-0.12	-0.12	-0.11	-0.07
Return on tangible assets	-1.01	-0.17	-0.16	-0.18	-0.09
Graham Net	-6.28	0.82	0.3	-0.77	-3.33
Working capital	68.33M	153.32M	128.91M	103.45M	123.52M
Tangible asset value	67.06M	145.33M	116.48M	78.13M	55.39M
Net current asset value	-24.62M	55.52M	33M	8.79M	-63.32M
Invested capital	0.29	0.23	0.25	0.29	0.25
Average receivables	43.6M	38.44M	33.73M	33.16M	32.61M
Average payables	66.45M	57.95M	47.45M	31.94M	24.56M
Average inventory	28.92M	13M	11.93M	10.44M	9.06M
Days sales outstanding	63.58	69.99	62.65	54.72	51.44
Days payables outstanding	53.32	225.42	75.16	124.75	28.94
Days of inventory on hand	15.83	39.78	34.65	30	24.81
Receivables turnover	1.42	1.29	1.44	1.64	1.75
Payables turnover	1.69	0.4	1.2	0.72	3.11
Inventory turnover	5.68	2.26	2.6	3	3.63
ROE	-1.22	-0.19	-0.16	-0.17	-0.11
Capex per share	-0.24	-0.02	-0.11	0	-0.09

SMFR Frequently Asked Questions

What is Sema4 Holdings Corp. stock symbol ?

Sema4 Holdings Corp. is a US stock , located in Stamford of Ct and trading under the symbol SMFR

Is Sema4 Holdings Corp. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $2.63. The lowest prediction is $1 and the highest is $3.5

What is SMFR stock prediction ?

What is Sema4 Holdings Corp. stock quote today ?

Sema4 Holdings Corp. stock price is $- today.

Is Sema4 Holdings Corp. stock public?

Yes, Sema4 Holdings Corp. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 2.01M
Market Capitalization 246.37M
Employee 1.2K
CEO Mr. Jason Ryan
Headquarters Stamford,CT,US
IPO Date 2020-11-04
Website https://www.sema4.com

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.